Adaptive Phage gets $10M from DoD for antibacterial phage therapies

MedCity News | January 08, 2020

Adaptive Phage gets $10M from DoD for antibacterial phage therapies
A company developing treatments for drug-resistant bacterial infections is getting a boost from the Department of Defense. Gaithersburg, Maryland-based Adaptive Phage Therapeutics, also known as APT, said Tuesday that it the DoD had awarded it $10.2 million to fund a clinical trial to develop its personalized bacteriophage therapeutic, PhageBank. “This is a promising step toward making phage therapy available to military and potentially non-military patients alike as a rapid and cost-effective option for multi-drug resistant bacterial infections,” APT CEO Greg Merril said in a statement. “APT’s proprietary technologies enable the rapid administration of phage therapy as a precise treatment tailored to a patient’s individual infection.”

Spotlight

Most of developments in biotechnology have taken place in a very short period of time, beginning with the discovery of molecular structure of DNA.

Related News

CELL AND GENE THERAPY

Curi Bio Closes $10M Series A in Oversubscribed Round

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform. “Curi Bio is thrilled to partner with the distinguished teams at UTC Investment, DS Asset Management, and Dynamk Capital to fuel our next stage of growth. To discover new therapies requires human-relevant disease models. Curi is working to close the gap between preclinical results and clinical outcomes, not only in small molecule discovery, but also in frontier areas like next-generation genetic medicines and cell therapies.” Michael Cho, JD, CEO of Curi Bio With costs to develop a single new medicine now exceeding $2Bn, the need for more human-relevant disease models to improve translational efficiency in the drug development process has never been greater. Curi’s core platform – the Curi Engine™ – integrates human stem cells, tissue specific biosystems, and A.I./M.L.-enabled data analysis to accelerate the discovery and development of new therapeutics. With this three-pronged strategy — human cells, systems and data — Curi is rapidly becoming a market leader in creating high-fidelity models of human diseases for drug discovery, especially for striated muscle, including cardiac and skeletal muscle, and neuromuscular models. “Curi Bio’s technology platforms create significant value for pharma and biotech companies by accelerating discovery timelines and increasing the chances of success for new therapies in development,” said Dr. Gustavo Mahler, Managing Partner, Dynamk Capital. “We look forward to strong growth in Curi Bio’s customer portfolio.” Curi Bio’s core technologies and products include NanoSurface™ Plates for structural maturation, Cytostretcher™ cell-stretching instruments, and the Mantarray platform for contractility analysis. The Mantarray platform enables researchers to generate and analyze 3D engineered human muscle tissues, providing clinically relevant functional readouts, and reducing reliance on poorly predictive animal models. Curi also offers a suite of customized research services utilizing the Curi Engine, including new assay and model development and phenotypic screening. Curi Bio counts all of the top-ten global pharmaceutical companies among its clients, customers, and partners. About Curi Bio Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. The company’s proprietary technologies are supported by over 100 publications and 19 patents. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

Read More

CELL AND GENE THERAPY

Thermo Fisher Scientific Announces its Complete Acquisition of Mesa Biotech

Thermo Fisher Scientific | March 01, 2021

Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization. Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and different settings, giving outcomes quickly. Past COVID-19 testing, Mesa Biotech's current stage incorporates tests for influenza, respiratory syncytial infection (RSV), and Strep A. "The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing. And, as the point-of-care diagnostic market expands globally, we're well-positioned to deliver a broader menu of tests to meet increasing demand," Stevenson continued. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Read More

Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, the key interaction that drives infection. As described in a recent pre-print on bioRxiv, this antibody did not show off-target binding to any human proteins on the MPA and is being progressed for further development."Integral Molecular's cutting-edge MPA technology quickly provided us with the reassurance that Abound Bio's potent, neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins which could be associated with toxicity," said John W. Mellors, MD, CEO of Abound Bio."Off-target antibody binding can induce serious adverse clinical events," said Dimiter Dimitrov, PhD, ScD, CSO of Abound Bio. "For this high-priority project, we relied on Integral Molecular's rapid specificity profiling to rule out liabilities arising from unexpected antibody cross-reactivity in human cells."Recent data show that as many as 25% of preclinical antibodies have off-target binding to unintended protein targets, which can lead to serious adverse events in patients. The MPA is a collection of 6,000 membrane proteins expressed in live cells, representing nearly the entire human membrane proteome. The MPA provides specificity results in less than a month, faster than traditional non-clinical safety studies. Rapidly eliminating drug candidates with off-target effects or other liabilities can accelerate the safe progression of therapeutics into the clinic.

Read More

Spotlight

Most of developments in biotechnology have taken place in a very short period of time, beginning with the discovery of molecular structure of DNA.